Table 4 Causes of infliximab discontinuation in ATIpos and ATIneg patientsa
Cause of discontinuation | ATIpos (n= 18) | ATIneg (n= 41) |
|---|---|---|
Treatment failure | ||
Primary failure | 2 (11%) | 23 (56%) |
Secondary failure | 3 (17%) | 8 (20%) |
Infusion reactions | 9 (50%) | 1 (2%) |
Adverse events | 1 (5.5%) | 6 (15%) |
Other | 1 (5.5%) | 2 (5%) |
Lost to follow-up | 2 (11%) | 1 (2%) |